Xgeva Matches Standard of Care in Delaying Bone Lesions in Multiple Myeloma Patients, Amgen Reports
Amgen announced that its RANKL inhibitor, Xgeva (denosumab) met…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Darzalex Combo Therapy Shows Promise in Relapsed or Refractory Multiple Myeloma Patients
A three-drug therapy combination consisting of Darzalex (…
Multiple Myeloma Studied in New Mouse Model Developed at Yale
Understanding how multiple myeloma develops and responds to therapies…
WT1 Vaccine Helped High-Risk Multiple Myeloma Patients After Stem Cell Transplant
High-risk multiple myeloma patients may benefit markedly from galinpepimut-S,…
UV Light Robots Reduced Hospital-Acquired Infections by 25%, Study Finds
Robots can do all sorts of tasks to improve…
FDA Grants Priority Review to Darzalex Combo Therapy for Relapsed Multiple Myeloma Patients
The U.S. Food and Drug Administration (FDA) is…
